scholarly journals Coping with an Advanced Stage Lung Cancer Diagnosis: Patient, Caregiver, and Provider Perspectives on the Role of the Health Care System

2015 ◽  
Vol 31 (3) ◽  
pp. 554-558 ◽  
Author(s):  
K M Islam ◽  
Samuel T Opoku ◽  
Bettye A Apenteng ◽  
Ann Fetrick ◽  
June Ryan ◽  
...  
Cancer ◽  
2017 ◽  
Vol 124 (2) ◽  
pp. 426-433 ◽  
Author(s):  
Donald R. Sullivan ◽  
Linda Ganzini ◽  
Jodi A. Lapidus ◽  
Lissi Hansen ◽  
Patricia A. Carney ◽  
...  

2012 ◽  
Vol 13 (6) ◽  
pp. 416-423 ◽  
Author(s):  
Valentina Monica ◽  
Marina Longo ◽  
Barbara Felice ◽  
Giorgio V. Scagliotti ◽  
Mauro Papotti ◽  
...  

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Brett C. Bade ◽  
Geliang Gan ◽  
Fangyong Li ◽  
Lingeng Lu ◽  
Lynn Tanoue ◽  
...  

Abstract Background Lung cancer survivors need more options to improve quality of life (QoL). It is unclear to what extent patients with advanced stage disease are willing to participate in home-based physical activity (PA) and if these interventions improve QoL. The goal of our study was to determine interest in participating in our 3-month home-based walking regimen in patients with advanced stage lung cancer. We used a randomized design to evaluate for potential benefit in PA and patient-reported outcomes. Methods We performed an open-label, 1:1 randomized trial in 40 patients with stage III/IV non-small cell lung cancer (NSCLC) evaluating enrollment rate, PA, QoL, dyspnea, depression, and biomarkers. Compared to usual care (UC), the intervention group (IG) received an accelerometer, in-person teaching session, and gain-framed text messages for 12 weeks. Results We enrolled 56% (40/71) of eligible patients. Participants were on average 65 years and enrolled 1.9 years from diagnosis. Most patients were women (75%), and receiving treatment (85%) for stage IV (73%) adenocarcinoma (83%). A minority of patients were employed part-time or full time (38%). Both groups reported low baseline PA (IG mean 37 (Standard deviation (SD) 46) vs UC 59 (SD 56) minutes/week; p = 0.25). The IG increased PA more than UC (mean change IG + 123 (SD 212) vs UC + 35 (SD 103) minutes/week; p = 0.051)). Step count in the IG was not statistically different between baseline (4707 step/day), week 6 (5605; p = 0.16), and week 12 (4606 steps/day; p = 0.87). The intervention improved EORTC role functioning domain (17 points; p = 0.022) with borderline improvement in dyspnea (− 13 points; p = 0.051) compared to UC. In patients with two blood samples (25%), we observed a significant increase in soluble PD-1 (219.8 (SD 54.5) pg/mL; p < 0.001). Conclusions Our pilot trial using a 3-month, home-based, mobile health intervention enrolled over half of eligible patients with stage III and IV NSCLC. The intervention increased PA, and may improve several aspects of QoL. We also identified potential biomarker changes relevant to lung cancer biology. Future research should use a larger sample to examine the effect of exercise on cancer biomarkers, which may mediate the association between PA and QoL. Clinical trial registration Clinicaltrials.gov (NCT03352245).


Lung Cancer ◽  
2018 ◽  
Vol 115 ◽  
pp. S34 ◽  
Author(s):  
J.S. Evans ◽  
R. Kitson ◽  
R. Shah ◽  
S. Li ◽  
S. Ghosh ◽  
...  

MicroRNA ◽  
2021 ◽  
Vol 10 ◽  
Author(s):  
Saiedeh Razi Soofiyani ◽  
Kamram Hosseini ◽  
Alireza Soleimanian ◽  
Liela Abkhooei ◽  
Akbar Mohammad Hoseini ◽  
...  

: MicroRNAs (miRNAs) are highly conserved non-coding RNAs involved in many physiological processes such as cell proliferation, inhibition, development of apoptosis, differentiation, suppresses tumorigenicity, and regulating cell growth. The description of the alterations of miRNA expression patterns in cancers will be helpful to recognize biomarkers for early detection and possible therapeutic intervention in the treatment of cancers. Recent studies have shown that miR-451 is broadly dysregulated in lung cancer and is a crucial agent in lung tumor progression. This review summarizes recent advances of the potential role of miR-451 in lung cancer diagnosis, prognosis, and treatment and provides an insight into the potential use of miR-451 for the development of advanced therapeutic methods in lung cancer.


Sign in / Sign up

Export Citation Format

Share Document